|Bid||10,675.00 x 0|
|Ask||10,700.00 x 0|
|Day's Range||10,180.00 - 11,490.00|
|52 Week Range||6,705.00 - 11,490.00|
|Beta (5Y Monthly)||0.50|
|PE Ratio (TTM)||72.84|
|Earnings Date||Aug 02, 2021 - Aug 06, 2021|
|Forward Dividend & Yield||160.00 (1.50%)|
|Ex-Dividend Date||Sep 29, 2021|
|1y Target Est||11,480.00|
Japan's Nikkei index closed higher on Thursday, as shipping firms rose on prospects of more economic reopenings and drugmakers were boosted by reports of government support. Signs that more economies are reopening amid a steady vaccine rollout underpinned shipping firms, with Nippon Yusen jumping 3.65% to be the biggest gainer on the Nikkei. Japan plans to finish vaccinating all citizens who have applied for shots by October-November, Prime Minister Yoshihide Suga said during a debate between party leaders on Wednesday.
Japanese shares inched higher on Thursday, as the service sector gained on prospects of economic reopenings and drugmakers rose on reports of government support, though Eisai eased after a big jump following U.S. approval of its Alzheimer's disease drug. Hopes of economic reopenings amid a steady vaccine rollout underpinned real-estate companies, railway operators and airline companies, though some of them started to lose momentum after a steady rally so far this month. Japan plans to finish vaccinating all citizens who have applied for shots by October-November, Prime Minister Yoshihide Suga said during a debate between party leaders on Wednesday.
Eisai is working on another promising drug candidate to combat Alzheimer's disease, and will benefit from a split of the profits for Aduhelm.